Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats
Authors
Keywords
-
Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 32, Issue 5, Pages 578-590
Publisher
SAGE Publications
Online
2018-03-01
DOI
10.1177/0269881118756061
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
- (2017) Ashleigh L Osborne et al. NEUROPSYCHOPHARMACOLOGY
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Neurocognition: Clinical and Functional Outcomes in Schizophrenia
- (2017) Martin Lepage et al. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
- Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
- (2016) Rajaa El Bekay et al. BRITISH JOURNAL OF PHARMACOLOGY
- Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
- (2016) Pelle L. Ishøy et al. DIABETES OBESITY & METABOLISM
- Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist
- (2016) Kenichi Katsurada et al. Journal of Diabetes Investigation
- Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients
- (2015) Ping Feng et al. ACTA PHARMACOLOGICA SINICA
- Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
- (2015) R. E. Nielsen et al. ACTA PSYCHIATRICA SCANDINAVICA
- Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice
- (2015) Paula L. McClean et al. BEHAVIOURAL BRAIN RESEARCH
- Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals
- (2015) A. Ramos-Miguel et al. NEUROSCIENCE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
- (2015) Marcus Lind et al. BMJ-British Medical Journal
- Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
- (2015) Marcus Lind et al. BMJ-British Medical Journal
- Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System
- (2015) Jennifer E. Richard et al. PLoS One
- Liraglutide Improves Pancreatic Beta Cell Mass and Function in Alloxan-Induced Diabetic Mice
- (2015) Kanako Tamura et al. PLoS One
- Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT)
- (2014) Helena M. de Wit et al. DIABETOLOGIA
- Dopamine signaling in the amygdala, increased by food ingestion and GLP-1, regulates feeding behavior
- (2014) Rozita H. Anderberg et al. PHYSIOLOGY & BEHAVIOR
- Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
- (2014) Fares Bassil et al. PROGRESS IN NEUROBIOLOGY
- Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice
- (2014) David Cheng et al. PSYCHOPHARMACOLOGY
- Impact of Antipsychotic Treatment on Attention and Motor Learning Systems in First-Episode Schizophrenia
- (2014) Sarah K. Keedy et al. SCHIZOPHRENIA BULLETIN
- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
- (2014) Pelle L Ishøy et al. BMJ Open
- Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
- (2013) Pelle L. Ishøy et al. AMERICAN JOURNAL OF PSYCHIATRY
- Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
- (2013) Katrina Weston-Green et al. CNS DRUGS
- Circuit mechanisms of GluA1-dependent spatial working memory
- (2013) Florian Freudenberg et al. HIPPOCAMPUS
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
- (2013) Christian Hölscher JOURNAL OF ENDOCRINOLOGY
- Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease
- (2013) Paula L. McClean et al. NEUROPHARMACOLOGY
- Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats
- (2013) A.M. Barr et al. NEUROSCIENCE
- Diabetes and Cognitive Deficits in Chronic Schizophrenia: A Case-Control Study
- (2013) Mei Han et al. PLoS One
- Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals
- (2013) M Bomba et al. Cell Death & Disease
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
- (2013) Louise E Robinson et al. BMJ Open
- Schizophrenia Is a Cognitive Illness
- (2013) René S. Kahn et al. JAMA Psychiatry
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis
- (2012) Kerry Hunter et al. BMC NEUROSCIENCE
- Relationship between metabolic syndrome and cognition in patients with schizophrenia
- (2012) Jean Pierre Lindenmayer et al. SCHIZOPHRENIA RESEARCH
- Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer’s disease by exendin-4
- (2011) Song Chen et al. AGE
- Neuroprotective properties of GLP-1: theoretical and practical applications
- (2011) Jens Juul Holst et al. CURRENT MEDICAL RESEARCH AND OPINION
- GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake
- (2011) Amber L. Alhadeff et al. ENDOCRINOLOGY
- Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels
- (2011) Katrina Weston-Green et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
- (2011) P. L. McClean et al. JOURNAL OF NEUROSCIENCE
- Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze test
- (2011) Oguz Mutlu et al. NEUROSCIENCE LETTERS
- Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats
- (2010) Katrina Weston-Green et al. BEHAVIOURAL BRAIN RESEARCH
- Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance
- (2010) D. W. Porter et al. DIABETES OBESITY & METABOLISM
- Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes
- (2010) A. Garber et al. DIABETES OBESITY & METABOLISM
- Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis
- (2010) V L Albaugh et al. MOLECULAR PSYCHIATRY
- The Antipsychotics Olanzapine, Risperidone, Clozapine and Haloperidol Are D2-Selective Ex Vivo but Not In Vitro
- (2010) Patrick N McCormick et al. NEUROPSYCHOPHARMACOLOGY
- A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model
- (2010) Heidi N. Boyda et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
- (2010) Carol Kilkenny et al. PLOS BIOLOGY
- Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
- (2009) S. M. Stahl et al. ACTA PSYCHIATRICA SCANDINAVICA
- Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
- (2009) Talib Abbas et al. BEHAVIOURAL BRAIN RESEARCH
- Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system
- (2009) Alison Hamilton et al. NEUROREPORT
- Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat
- (2008) G. C. Smith et al. DIABETOLOGIA
- Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
- (2008) Stefan Leucht et al. LANCET
- Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine
- (2008) Nima Davoodi et al. PSYCHOPHARMACOLOGY
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
- (2008) Kirsten Lykkegaard et al. SCHIZOPHRENIA RESEARCH
- d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats
- (2007) Jun-ichi Karasawa et al. BEHAVIOURAL BRAIN RESEARCH
- Dose translation from animal to human studies revisited
- (2007) Shannon Reagan-Shaw et al. FASEB JOURNAL
- Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: Implications for animal models of antipsychotic-induced weight gain
- (2007) G.D. Cooper et al. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now